China pharma announces receipt of noncompliance notice from nyse american

Haikou, china , dec. 2, 2022 /prnewswire/ -- china pharma holdings, inc. (nyse american: cphi) ("china pharma," the "company" or "we"), a specialty pharmaceutical company, today announced that on december 1, 2022, received a notification (the "deficiency letter") from the nyse american llc (the "nyse american") stating that the company was not in compliance with a certain nyse american continued listing standard relating to stockholders' equity, or section 1003(a)(ii) of the nyse american company guide, which requires an issuer to have stockholders' equity of $4.0 million or more if it has reported losses from continuing operations and/or net losses in its four most recent fiscal years. the deficiency letter noted that company had stockholders' equity of $2.8 million as of september 30, 2022, and has reported losses from continuing operations and/or net losses in its four most recent fiscal years ended december 31, 2021.
CPHI Ratings Summary
CPHI Quant Ranking